| scholarly article | Q13442814 |
| P2093 | author name string | Anne Messer | |
| Tyisha Hathorn | |||
| Abigail Snyder-Keller | |||
| P2860 | cites work | Early or Late-Stage Anti-N-Terminal Huntingtin Intrabody Gene Therapy Reduces Pathological Features in B6.HDR6/1 Mice | Q41968546 |
| Exploring the relationship between serotonin and brain-derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. | Q42471590 | ||
| Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice | Q44619618 | ||
| Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases | Q44978542 | ||
| Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease. | Q45288502 | ||
| Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice | Q45293000 | ||
| Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. | Q45299732 | ||
| Decreased expression of striatal signaling genes in a mouse model of Huntington's disease | Q45300376 | ||
| Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease. | Q45300820 | ||
| Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. | Q45302702 | ||
| Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration | Q45302924 | ||
| Transcription meets metabolism in neurodegeneration | Q45303085 | ||
| Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease | Q45306894 | ||
| High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease. | Q46669769 | ||
| Enhancement of brain choline levels by nicotinamide: mechanism of action | Q48421891 | ||
| Motor coordination and balance in rodents | Q81130733 | ||
| Regional expression of constitutive and inducible transcription factors following transient focal ischemia in the neonatal rat: influence of hypothermia | Q81480594 | ||
| A suppressor of mating-type locus mutations in Saccharomyces cerevisiae: evidence for and identification of cryptic mating-type loci | Q24533488 | ||
| Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau | Q24651880 | ||
| PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis | Q24798075 | ||
| Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase | Q27860668 | ||
| Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes | Q28189644 | ||
| Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease | Q28202050 | ||
| Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1 | Q28203762 | ||
| SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha} | Q28235481 | ||
| Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation | Q28246858 | ||
| Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism | Q28266830 | ||
| Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha | Q28274682 | ||
| Biological and potential therapeutic roles of sirtuin deacetylases | Q28295339 | ||
| Modulation of SIRT1 expression in different neurodegenerative models and human pathologies | Q28564886 | ||
| Histone acetyltransferases | Q29547823 | ||
| Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice | Q29614547 | ||
| Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice | Q29615357 | ||
| Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila | Q29616737 | ||
| Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain | Q29617982 | ||
| N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking | Q30486372 | ||
| Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease | Q30493159 | ||
| Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. | Q33914222 | ||
| Safety of high-dose nicotinamide: a review | Q33928940 | ||
| Transcriptional dysregulation in Huntington's disease | Q34001953 | ||
| Brain-derived neurotrophic factor in neurodegenerative diseases | Q34017880 | ||
| Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease | Q34077018 | ||
| Trinucleotide repeat length instability and age of onset in Huntington's disease | Q34357407 | ||
| Polyglutamine diseases: emerging concepts in pathogenesis and therapy | Q34696955 | ||
| Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease | Q34763178 | ||
| Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease | Q35176635 | ||
| Histone deacetylase inhibitors as therapeutics for polyglutamine disorders | Q36599926 | ||
| PGC-1alpha, a new therapeutic target in Huntington's disease? | Q36643257 | ||
| Sirtuins as potential targets for metabolic syndrome | Q36682665 | ||
| Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. | Q36967971 | ||
| Medicine. The yin-yang of sirtuins | Q40101855 | ||
| Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus. | Q40632082 | ||
| Brain-derived neurotrophic factor regulates energy expenditure through the central nervous system in obese diabetic mice | Q40736919 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| niacinamide | Q192423 | ||
| P304 | page(s) | 43-50 | |
| P577 | publication date | 2010-08-22 | |
| P1433 | published in | Neurobiology of Disease | Q15716606 |
| P1476 | title | Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease | |
| P478 | volume | 41 |
| Q58584663 | Bioenergetics in fibroblasts of patients with Huntington disease are associated with age at onset |
| Q30613057 | Cerebellar transcriptional alterations with Purkinje cell dysfunction and loss in mice lacking PGC-1α. |
| Q39427235 | Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington's Disease Models |
| Q37947984 | Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. |
| Q34023773 | D-β-hydroxybutyrate is protective in mouse models of Huntington's disease |
| Q35403365 | Differential effect of HDAC3 on cytoplasmic and nuclear huntingtin aggregates. |
| Q90512417 | Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide |
| Q37961564 | Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins |
| Q36848454 | Epigenetics in nucleotide repeat expansion disorders |
| Q24619820 | Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency |
| Q99557279 | IRF1-mediated downregulation of PGC1α contributes to cardiorenal syndrome type 4 |
| Q57462990 | Increased mortality in mice following immunoprophylaxis therapy with high dosage of nicotinamide in persistent infections |
| Q64085065 | Integration of the Deacetylase SIRT1 in the Response to Nucleolar Stress: Metabolic Implications for Neurodegenerative Diseases |
| Q27003896 | Intrabodies as neuroprotective therapeutics |
| Q34406937 | Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's disease. |
| Q28394301 | Metabolism in HD: still a relevant mechanism? |
| Q27005950 | Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. |
| Q90438582 | NAD+ in Brain Aging and Neurodegenerative Disorders |
| Q100490695 | NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential |
| Q64108314 | Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications |
| Q33800897 | Nicotinamide Administration Improves Remyelination after Stroke |
| Q47556627 | Nicotinamide Inhibits Ethanol-Induced Caspase-3 and PARP-1 Over-activation and Subsequent Neurodegeneration in the Developing Mouse Cerebellum |
| Q30537554 | Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession |
| Q28730781 | Nicotinamide, NAD(P)(H), and Methyl-Group Homeostasis Evolved and Became a Determinant of Ageing Diseases: Hypotheses and Lessons from Pellagra |
| Q42792348 | Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease |
| Q38246221 | Potential therapeutic targets in polyglutamine-mediated diseases |
| Q38191477 | Prospects for neuroprotective therapies in prodromal Huntington's disease |
| Q37093737 | Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease |
| Q30418644 | Reelin is a target of polyglutamine expanded ataxin-7 in human spinocerebellar ataxia type 7 (SCA7) astrocytes |
| Q38104654 | Role of BDNF in central motor structures and motor diseases. |
| Q28386202 | Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis |
| Q38186171 | SIRT1 in neurodevelopment and brain senescence |
| Q28482270 | SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo |
| Q64262007 | Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models |
| Q48331352 | Silent information regulator 1 modulator resveratrol increases brain lactate production and inhibits mitochondrial metabolism, whereas SRT1720 increases oxidative metabolism |
| Q26772894 | Sirt1 and the Mitochondria |
| Q36863901 | Targeting sirtuin-1 in Huntington's disease: rationale and current status |
| Q54968514 | The Influence of Nicotinamide on Health and Disease in the Central Nervous System. |
| Q39313679 | The emerging field of epigenetics in neurodegeneration and neuroprotection |
| Q36037085 | The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice |
| Q64859138 | The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease |
| Q28087539 | The promise and perils of HDAC inhibitors in neurodegeneration |
| Q54965657 | Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies. |
| Q27026549 | Transcriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasis |
| Q87241483 | [Huntington's disease] |
Search more.